


Actualities of Hungarian pharmaceutical financing market



22

0,7

nding an e-mail to

0,5

Source: Healthware analysis based on NHIFA data

Healthware Consulting Ltd.

Average of last 6

months

H-1133 Budapest, Váci út 76. 7.em. 2. tor. + 36-1-324-2050

in <u>Subscribe</u>

1.8



Foplists of reimbursement and number of patients, N	lay 2024			
TOP 10 ATCs by all reimbursement paid		TOP 10 DOT by all reimbursement paid		
semaglutide	1 470 M H48,7	71 M	colecalciferol	
adalimumab	1 402 M HUF	22,62 M	perindopril and amlodipin	
enoxaparin	1 388 M HUF	22,09 M	rosuvastatin	
apixaban 1 377 M HUF		16,3	16,36 M perindopril and diuretics	
uxolitinib 1 235 M HUF		16	16,27 M pantoprazole	
other nutrients 997 M			11,59 M ramipril	
rivaroxaban 676 M HUF			10,84 M nebivolol	
enzalutamide 664 M HUF	22%	38%	10,30 M atorvastatin	
enzalutamide 664 M HUF insuline degludec and liraglutid;32 M HUF			10,23 M amlodipine	
rrce: Pharmacy turnover data, Healthware analysis			10,03 M perindopril Source: Pharmacy turnover data, Healthware analysis	
OP 10 distributors by all reimbursement paid		TOP 10 patient turnover by all reimbursement pa		
Novartis	4 428		many -	
)73 M HUF	77,133	pantoprazole	
	MHUF	271,336	didretics	
		264,487	a. The Y	
		240,057	nebivolol	
Sanofi-Aventis 2 645 M			bisoprolol	
Sandoz 2 474 M HUF		203,298		
Egis 2 159 M HUF		203,190	t t t t t t t t t t t t t t allopurinol	
Boehringer 1 522 M HUF		174,936 ************** perindopril		
AstraZeneca 1 383 M HUF		174,868 11111111111111111111111111111111111		
Teva 1 307 M HUF				
urce: Pharmacy turnover data, Healthware analysis		Product shortages	ource: Pharmacy turnover data, Healthware analysis	
ubstitutable products, May 2024				
Within product deletions, marketing authorization (MAH) erasures were distinguished. We also examined the active substances and brands affected in the procedure. These were divided into two groups according to whether the brand or active substance was completely <u>removed</u> from the formulary or whether there remained (affected) at least one product that belonged to the active substance or brand.		The graph shows the distribution of the reimbursed product shortage list. 488 products had been on the list before May 2024, compared to 47 new product added to the list in the month under review. The 47 newly listed products were grouped according to the number of reimbursed substitutes. Based on this criterion, 4 groups were formed: products with 3 or more, exactly 2, exactly 1 and 0 reimbursed substitutes.		
Affected Deleted		A7	ursed substitutes	
13 O Brand				
Affected Deleted			2 0	
8 0 INN		400	1	
		488	3 7 2	
Affected	MAH erasures			
21	11		3+	

Source: Pharmacy turnover data, Healthware analysis

In May 2024, no product shortages were reported for a product without a pharmacy substitute.

lent substitutes established by the National Centre for Public Health and Pharmacy

**Turnover in the 12 months preceding the product shortage

Source: Pharmacy turnover data, Healthware analysis

Ranking

<u>sanofi</u>

-

MERCK

KR .

7 CHEPLAPHARM

AMGEN

R

1

2

3

4

5

6

8

9

10

Brand

LIBTAYO

OCREVUS

FINTEPLA

MAVENCLAD

RYBELSUS

OFEV

LOKREN

NPLATE

OZEMPIC

TRULICITY

ared to the average of the 6 months preceding the reference month Source: Pharmacy turnover data, Healthware analysi:

Source: Pharmacy turnover data, Healthware analysis

%*

178%

135%

155%

118%

126%

119%

137%

137%

109%

84%

Unsubscribe

Reimbursement increment

100 068 837 HUF

48 747 316 HUF

42 191 938 HUF

41 632 305 HUF

40 641 537 HUF

38 148 878 HUF

37 010 791 HUF

34 449 360 HUF

32 311 791 HUF

30 777 020 HUF

Subscribe

*Com